Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osilodrostat in Children and Adolescent Patients With Cushing's Syndrome
NCT03708900Phase 2Recruiting
- Sponsor
- Recordati SpA
- Start
- Apr 2021
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of osilodrostat in Cushing syndrome, sponsored by Recordati SpA. Primary endpoint: Pharmacokinetics. Started Apr 2021; status: recruiting.
02
Drugs
osilodrostat
03
Conditions
Cushing syndrome
Beyond the preview
Go deeper on NCT03708900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03708900.